drugset / Trial / NCT00109759

Evaluation of Safety and Tolerability of Tyrosine Adsorbed Ragweed Pollen Allergoid With MPL (Monophosphoryl Lipid A)

NCT00109759 ↗

Phase 1 Withdrawn Allergy Therapeutics
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The safety and tolerability of tyrosine adsorbed ragweed pollen allergoid with monophosphoryl lipid A (MPL) was planned to be evaluated. For this purpose, a total of 4 injections of either increasing doses of the study drug or placebo (tyrosine) was planned to be administered in 7-day intervals to healthy volunteers.

Timeline

Start
2005-05
Primary completion
—
Completion
2005-06

Drugs

EvaluationDrugModalityDoseRoute
Subject RagweedMATAMPL Other / unclassified — Subcutaneous